Home › Crohn's Disease › Maryland
Crohn's Disease clinical trials in Maryland
15 studies for Crohn's Disease are looking for participants at sites in Maryland.
Cities in Maryland
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT03816345A Study of SL-325 in Crohn's Disease Patients
- Clinical Trial Site, Glen Burnie
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Nov 12, 2026 · NCT07753850Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 18 to 85 · All sexes · Updated Nov 10, 2026 · NCT07619547A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Walter Reed National Military Medical Center ( Site 5006), Bethesda
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Nov 10, 2026 · NCT06430801Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Capital Digestive Care - Chevy Chase, Chevy Chase
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Nov 4, 2026 · NCT06937099A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- Chevy Chase Clinical Research, Chevy Chase
- Woodholme Gastroenterology Associates, Glen Burnie
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07196722A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Woodholme Gastroenterology Associates, Glen Burnie
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07499232An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1/2
Ages 18 to 65 · All sexes · Updated Nov 2, 2026 · NCT03167437A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- Woodholme Gastroenterology Associates, Glen Burnie
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Nov 2, 2026 · NCT06233461A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Capital Digestive Care, Chevy Chase
- Woodholme Gastroenterology, Glen Burnie
RecruitingPhase 4
Ages 18 to 80 · All sexes · Updated Oct 28, 2026 · NCT06581328An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Mercy Medical Center, Baltimore-Site Number: 8400117, Baltimore
- Mid-Atlantic GI Research, LLC-Site Number: 8400106, Laurel
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Oct 21, 2026 · NCT07184931Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Metropolitan Gastroenterology Group - Chevy Chase /ID# 265877, Chevy Chase
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT06548542Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- Mercy Medical Center, Baltimore
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT07237516A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
- Woodholme Gastroenterology Associates, Glen Burnie
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated May 22, 2026 · NCT06764615A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
- Johns Hopkins University, Baltimore
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated May 5, 2026 · NCT04779320From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.